These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2494630)

  • 21. Maf and Nrl can bind to AP-1 sites and form heterodimers with Fos and Jun.
    Kerppola TK; Curran T
    Oncogene; 1994 Mar; 9(3):675-84. PubMed ID: 8108109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of action of a dominant-negative mutant of c-Jun.
    Brown PH; Chen TK; Birrer MJ
    Oncogene; 1994 Mar; 9(3):791-9. PubMed ID: 8108121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rat maf-related factors: the specificities of DNA binding and heterodimer formation.
    Matsushima-Hibiya Y; Nishi S; Sakai M
    Biochem Biophys Res Commun; 1998 Apr; 245(2):412-8. PubMed ID: 9571165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single site mutation in a truncated Fos protein allows it to interact with the TRE in vitro.
    Nicklin MJ; Casari G
    Oncogene; 1991 Jan; 6(1):173-9. PubMed ID: 1899479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
    Echlin DR; Tae HJ; Mitin N; Taparowsky EJ
    Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrity of FOS B leucine zipper is essential for its interaction with JUN proteins.
    Ryseck RP; Kovary K; Bravo R
    Oncogene; 1990 Jul; 5(7):1091-3. PubMed ID: 2115643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transformation by Jun: requirement for leucine zipper, basic region and transactivation domain and enhancement by Fos.
    Morgan IM; Ransone LJ; Bos TJ; Verma IM; Vogt PK
    Oncogene; 1992 Jun; 7(6):1119-25. PubMed ID: 1594243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterodimerization with c-Fos is not required for cell transformation of chicken embryo fibroblasts by Jun.
    Hughes M; Sehgal A; Hadman M; Bos T
    Cell Growth Differ; 1992 Dec; 3(12):889-97. PubMed ID: 1472469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transactivation activity of Maf nuclear oncoprotein is modulated by Jun, Fos and small Maf proteins.
    Kataoka K; Noda M; Nishizawa M
    Oncogene; 1996 Jan; 12(1):53-62. PubMed ID: 8552399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK.
    Deng T; Karin M
    Nature; 1994 Sep; 371(6493):171-5. PubMed ID: 8072547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The oncogenicity of jun.
    Vogt PK; Bos TJ; Mitsunobu F; Nishimura T; Monteclaro FS; Su HY
    Princess Takamatsu Symp; 1989; 20():127-34. PubMed ID: 2562177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
    Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
    Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A conserved region adjacent to the basic domain is required for recognition of an extended DNA binding site by Maf/Nrl family proteins.
    Kerppola TK; Curran T
    Oncogene; 1994 Nov; 9(11):3149-58. PubMed ID: 7936637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a sensitive peptide-based immunoassay: application to detection of the Jun and Fos oncoproteins.
    Heuer KH; Mackay JP; Podzebenko P; Bains NP; Weiss AS; King GF; Easterbrook-Smith SB
    Biochemistry; 1996 Jul; 35(28):9069-75. PubMed ID: 8703910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Jun, the oncoprotein.
    Vogt PK
    Oncogene; 2001 Apr; 20(19):2365-77. PubMed ID: 11402333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts.
    Basso J; Briggs J; Findlay C; Bos T
    Oncogene; 2000 Oct; 19(42):4876-85. PubMed ID: 11039905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo viral and cellular Jun complexes exhibit differential interaction with a number of in vitro generated 'AP-1- and CREB-like' target sequences.
    Hadman M; Loo M; Bos TJ
    Oncogene; 1993 Jul; 8(7):1895-903. PubMed ID: 8510933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains.
    Gentz R; Rauscher FJ; Abate C; Curran T
    Science; 1989 Mar; 243(4899):1695-9. PubMed ID: 2494702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The leucine repeat motif in Fos protein mediates complex formation with Jun/AP-1 and is required for transformation.
    Schuermann M; Neuberg M; Hunter JB; Jenuwein T; Ryseck RP; Bravo R; Müller R
    Cell; 1989 Feb; 56(3):507-16. PubMed ID: 2492453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex.
    Butticè G; Duterque-Coquillaud M; Basuyaux JP; Carrère S; Kurkinen M; Stéhelin D
    Oncogene; 1996 Dec; 13(11):2297-306. PubMed ID: 8957070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.